Health Care · Services-Commercial Physical & Biological Research · NYSE · CIK 1100682 · FYE Dec 27 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $234.80Day −2.34%Mkt cap $11.3B1Y +31.6%Off 52W high −3.3%Vol (1Y) 45.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 58.9% growth |
| Short interest6.9% of sh out |
| Days to cover4.0d |
| 13F net flow (QoQ)+11.95% |
| Top-10 13F concentration42.5% |
| Next report (est.)2026-08-06 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$4.03B |
| Earnings (TTM)-$184.7M |
| ROE−4.4% |
| Net margin−3.6% |
| ROIC0.6% |
| Debt / equity0.00× |
| YTD+17.7% |
| 1Y+31.6% |
| 3Y+12.1% |
| 5Y−42.1% |
| 10Y+167.0% |
| Since incept. (ann.)+7.6% |
Total return through 2026-07-29 · series begins 2005-07-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)45.8% |
| Ann. volatility (3Y)45.4% |
| Sharpe (1Y)0.83 |
| Sharpe (3Y)0.31 |
| Max drawdown (1Y)−33.9% |
| Max drawdown (3Y)−63.5% |
| Beta (3Y vs SPY)1.33 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 3.9M | $666M | — | +2.8% |
| FMR LLC | 3.5M | $596M | — | +99.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2M | $552M | — | new |
| Invesco Ltd. | 2.4M | $414M | — | −11.1% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.3M | $396M | — | new |
| HARRIS ASSOCIATES L P | 2.2M | $371M | — | +28.4% |
| Allspring Global Investments Holdings, LLC | 2.0M | $349M | — | −0.1% |
| STATE STREET CORP | 1.9M | $323M | — | +0.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (57,607,049) exceed the latest reported shares-outstanding count (48,167,730) by more than securities-lending double counting can explain (FINRA short interest 3,349,211 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-28 | 2026-05-07 | −$0.30 | −160.0% | $995.8M | +1.2% |
| 2025-12-27 | 2026-02-18 | — | — | $994.2M | −0.8% |
| 2025-09-27 | 2025-11-05 | $1.10 | −17.3% | $1.00B | −0.5% |
| 2025-06-28 | 2025-08-06 | $1.06 | −39.1% | $1.03B | +0.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Discovery And Safety Assessment 60% · Research Models And Services 21% · Manufacturing Support 19%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Total debt / EBITDA0.00× |
| Sales growth 3Y0.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
